| All Releases |
|---|
 |
Orexigen(R) Initiates Second Phase IIb Empatic™ Trial on Schedule
Jul 9, 2008
|
13.7 KB
|
| |
SAN DIEGO, July 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced today that it has begun randomizing patients in ZB-202, a second Phase IIb clinical trial for Empatic(TM), one of the Company's two late-stage obesity product candidates. The trial is designed to build on highly encourag...
|
|
|
Orexigen(R) Therapeutics to Discuss Two Advanced-Stage Obesity Products That Target the Brain's Critical Role in Regulating Body Weight
Jun 12, 2008
|
13.7 KB
|
| |
SAN DIEGO, Jun 12, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders, including obesity, is scheduled to present an overview of its novel understanding of the current obesity epidemic. This understanding is the basis of new strategies...
|
|
|
Orexigen(R) Therapeutics Announces That Contrave(R) May Reverse the Incidence of Metabolic Syndrome
Jun 7, 2008
|
13.5 KB
|
| |
SAN FRANCISCO & SAN DIEGO, Jun 07, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that based on a review of data from its Contrave(R) Phase IIb trial, patients assigned to Contrave dosage groups demons...
|
|
|
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Jun 4, 2008
|
9.6 KB
|
| |
SAN DIEGO, Jun 04, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:
Canaccord Adams Diabetes and Obesity Conferenc...
|
|
|
Orexigen(R) Therapeutics Issued a Key U.S. Patent Covering Composition of Contrave(R) into 2025
May 27, 2008
|
12.4 KB
|
| |
SAN DIEGO, May 27, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Number 7,375,111 with broad claims covering sustained release (SR)...
|
|
|
Orexigen(R) Therapeutics Announces First Quarter 2008 Financial Results
May 8, 2008
|
20.0 KB
|
| |
SAN DIEGO, May 08, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced unaudited financial results for the three months ended March 31, 2008.
Three months ended March 31, 2008
As of March 31, 2008, ...
|
|
|
Orexigen(R) Therapeutics Announces Completion of Patient Enrollment in Phase III Clinical Program for Contrave(R)
May 7, 2008
|
13.0 KB
|
| |
SAN DIEGO, May 07, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced completion of enrollment in NB-303 and NB-304, the final two Phase III clinical trials for Contrave(R), its lead obesity product candid...
|
|
|
Orexigen(R) Therapeutics to Announce First Quarter 2008 Financial Results on May 8, 2008 at 5:00 p.m. Eastern
May 6, 2008
|
10.0 KB
|
| |
SAN DIEGO, May 06, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, will announce its first quarter 2008 financial results on Thursday, May 8, 2008 after the markets close. The announcement will be followed by a live con...
|
|
|
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
May 5, 2008
|
9.3 KB
|
| |
SAN DIEGO, May 05, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:
NeuroInsights 3rd Annual Neurotech Industry In...
|
|
|
Orexigen(R) Therapeutics Announces Completion of Enrollment in Second of Four Phase III Clinical Trials for Contrave(R)
Apr 22, 2008
|
12.8 KB
|
| |
SAN DIEGO, Apr 22, 2008 (BUSINESS WIRE) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced completion of enrollment in NB-301, the largest of its Phase III clinical trials, for Contrave(R), its lead obesity product candidate. ...
|
|
|
OREXIGEN™ Therapeutics Announces Fourth Quarter and Year Ended December 31, 2007 Financial Results
Mar 13, 2008
|
20.6 KB
|
| |
SAN DIEGO, Mar 13, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced financial results for the three months and year ended December 31, 2007.
Three months ended December 31, 2007
As of December 3...
|
|
|
OREXIGEN™ Therapeutics to Present at Upcoming Investor Conferences
Mar 12, 2008
|
9.5 KB
|
| |
SAN DIEGO, Mar 12, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:
Cowen and Company Health Care Conference
Mar...
|
|
|
OREXIGEN™ Therapeutics to Announce Fourth Quarter and Full-Year 2007 Financial Results in Webcast March 13, 2008
Mar 11, 2008
|
10.0 KB
|
| |
SAN DIEGO, Mar 11, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, will announce its fourth quarter and year ended December 31, 2007 financial results on Thursday, March 13, 2008 after the markets close. The announceme...
|
|
|
OREXIGEN™ Therapeutics Appoints Carol Baum as Vice President of Commercialization
Mar 10, 2008
|
9.8 KB
|
| |
SAN DIEGO, Mar 10, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that Carol Baum assumed the position of Vice President of Commercialization effective today. Ms. Baum brings to Orexigen over twelve y...
|
|
|
OREXIGEN™ Therapeutics Announces European Patent Office Allows Composition and Use Claims for its Patent on Contrave™ to Treat Obesity
Feb 28, 2008
|
11.8 KB
|
| |
SAN DIEGO, Feb 28, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the European Patent Office has issued a Decision to Grant a Patent covering compositions and uses of bupropion and naltrexone for...
|
|
|
OREXIGEN™ Therapeutics Announces Notice of Allowance for U.S. Patent Strengthening Exclusivity for Empatic™ for Obesity
Feb 21, 2008
|
11.6 KB
|
| |
SAN DIEGO, Feb 21, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application providing...
|
|
|
OREXIGEN™ Therapeutics Announces Exercise of Overallotment Option by Underwriters
Feb 7, 2008
|
9.7 KB
|
| |
SAN DIEGO, Feb 07, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq: OREX) announced today the that its underwriters partially exercised their overallotment option to purchase an additional 326,435 shares of its common stock in connection with its previously announced public offering that priced on January 23, 2008. Including the ove...
|
|
|
OREXIGEN™ Therapeutics Announces Notice of Allowance for U.S. Patent Extending Exclusivity for Composition of Contrave™ to 2024
Jan 31, 2008
|
11.6 KB
|
| |
SAN DIEGO, Jan 31, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that a Notice of Allowance has been electronically posted by the United States Patent and Trademark Office (USPTO) for a patent applic...
|
|
|
OREXIGEN™ Therapeutics to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Jan 31, 2008
|
8.9 KB
|
| |
SAN DIEGO, Jan 31, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference. The confer...
|
|
|
Orexigen Therapeutics Announces Pricing of Its Follow-on Offering
Jan 24, 2008
|
9.5 KB
|
| |
SAN DIEGO, Jan 24, 2008 (BUSINESS WIRE) -- Orexigen(TM) Therapeutics, Inc. (NASDAQ: OREX) today announced the public offering of 7,000,000 shares of common stock at a price of $11.00 per share. All shares are being offered by Orexigen. In addition, Orexigen has granted the underwriters a 30-day option to purchase an additional 1,050,000 shares to c...
|
|
|
|
